62421-17-4

Basic information

• Product Name: (+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE
• Synonyms: (+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE;2,3-Naphthalenediol,6-(dipropylamino)-5,6,7,8-tetrahydro-,hydrobromide;2,3-Naphthalenediol, 6-(dipropylamino)-5,6,7,8-tetrahydro-, hydr;TL 232 hydrobromide
• CAS NO: 62421-17-4
• Molecular Formula: C16H25NO2.BrH
• Molecular Weight: 0
• Mol File: 62421-17-4.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE(CAS DataBase Reference)
• NIST Chemistry Reference: (+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE(62421-17-4)
• EPA Substance Registry System: (+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE(62421-17-4)

Safety Data

• Hazardous Substances Data: 62421-17-4(Hazardous Substances Data)

Usage

General Description

(+/-)-2-DIPROPYLAMINO- 6,7-DIHYDROXY-1,2,3,4-TETRAHYDRONAPHTHALENE, also known as droxidopa, is a synthetic amino acid precursor that is used in the treatment of orthostatic hypotension. It is structurally similar to norepinephrine, a neurotransmitter that regulates blood pressure and heart rate. Droxidopa is converted to norepinephrine in the body, leading to increased blood pressure and improved symptoms of orthostatic hypotension. It is available in oral capsule form and is typically used in combination with other medications for the management of this condition. Droxidopa has been approved by the FDA for use in the United States since 2014 and is considered an important therapeutic option for patients with orthostatic hypotension.